Seaside Therapeutics' Drug May Help Some Autism Cases
9/20/2012 8:18:12 AM
More...
|
Seaside Therapeutics Named a “Fierce 15” Biotech Company for 2012
9/19/2012 9:51:43 AM
More...
|
Roche (RHHBY), Seaside Therapeutics to Research Autism Treatments
6/19/2012 6:34:06 AM
More...
|
Seaside Therapeutics Announces Issuance of Key Patent for Lead Autism Candidate STX209
3/28/2012 7:15:59 AM
More...
|
Seaside Therapeutics Presents Data on Potential Pharmaceutical Treatment for Improving Social Impairment in Autism Spectrum Disorders at 42nd Autism Society National Conference
7/11/2011 10:02:40 AM
More...
|
Seaside Therapeutics Initiates Phase 2b Study of STX209 in Autism Spectrum Disorders
6/21/2011 8:41:08 AM
More...
|
Seaside Therapeutics Initiates Pivotal Phase 3 Study of STX209 in Fragile X Syndrome
6/2/2011 10:38:41 AM
More...
|
Seaside Therapeutics Publishes Review of Advances in the Treatment of Fragile X Syndrome in American Chemical Society Chemical Neuroscience
5/18/2011 9:50:18 AM
More...
|
Seaside Therapeutics Reports Positive Data from Phase 2 Study of STX209 in Autism Spectrum Disorders
9/9/2010 11:25:06 AM
More...
|
Seaside Therapeutics Reports Data from Randomized, Placebo-Controlled Phase 2 Study in Fragile X Syndrome
7/26/2010 8:27:58 AM
More...
|
|